PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
نویسندگان
چکیده
Fibrotic diseases are characterized by the accumulation of extracellular matrix together with distortion and disruption of tissue architecture. Phosphodiesterase (PDE)4 inhibitors, by preventing the breakdown of cAMP, can inhibit fibroblast functions and may be able to mitigate tissue remodeling. Transforming growth factor (TGF)-beta1, a mediator of fibrosis, can potentially modulate cAMP by altering PGE(2) metabolism. The present study assessed whether PDE4 inhibitors functionally antagonize the profibrotic activity of fibroblasts stimulated by TGF-beta1. The PDE4 inhibitors roflumilast and rolipram both inhibited fibroblast-mediated contraction of three-dimensional collagen gels and fibroblast chemotaxis toward fibronectin in the widely studied human fetal lung fibroblast strain HFL-1 and several strains of fibroblasts from adult human lung. Roflumilast was approximately 10-fold more potent than rolipram. There was a trend for PDE4 inhibitors to inhibit more in the presence of TGF-beta1 (0.05 < P < 0.08). The effect of the PDE4 inhibitors was mediated through cAMP-stimulated protein kinase A (PKA), although a PKA-independent effect on gel contraction was also observed. The effect of PDE4 inhibitors depended on fibroblast production of PGE(2) and TGF-beta1-induced PGE(2) production. PDE4 inhibitors together with TGF-beta1 resulted in augmented PGE(2) production together with increased expression of COX mRNA and protein. The present study supports the concept that PDE4 inhibitors may attenuate fibroblast activities that can lead to fibrosis and that PDE4 inhibitors may be particularly effective in the presence of TGF-beta1-induced fibroblast stimulation.
منابع مشابه
The PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-β1 stimulated fibroblasts
Fibrotic diseases are characterized by the accumulation of extracellular matrix together with distortion and disruption of tissue architecture. Phosphodiesterase 4 (PDE4) inhibitors, by preventing the breakdown of cyclic AMP, can inhibit fibroblast functions and may be able to mitigate tissue remodeling. TGF-β1, a mediator of fibrosis, can potentially modulate cAMP by altering PGE2 metabolism. ...
متن کاملPDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF- 1-stimulated fibroblasts
Shinsaku Togo, Xiangde Liu, Xingqi Wang, Hisatoshi Sugiura, Koichiro Kamio, Shin Kawasaki, Tetsu Kobayashi, Ronald F. Ertl, Youngsoo Ahn, Olaf Holz, Helgo Magnussen, Karin Fredriksson, C. Magnus Skold, and Stephen I. Rennard Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, Nebraska; Third Department of Internal Medicine, Wakayama Medical University, Wakayama; ...
متن کاملInhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram.
Piclamilast is a type 4 phosphodiesterase (PDE4) inhibitor with equal affinity for the high-affinity rolipram binding site (HARBS) and low-affinity rolipram binding site (LARBS). The binding of [(3)H]piclamilast to preparations of rat brain and peripheral tissue was investigated and compared with that of [(3)H]rolipram. [(3)H]piclamilast binding was high-affinity, saturable, reversible, and par...
متن کاملGSK256066, An Exceptionally High Affinity and Selective Inhibitor of PDE4 Suitable for Administration by Inhalation: In vitro, Kinetic and In vivo Characterisation
Oral phosphodiesterase (PDE) 4 inhibitors such as roflumilast have established the potential of PDE4 inhibition for the treatment of respiratory diseases. However, PDE4 inhibitor efficacy is limited by mechanism-related side effects such as emesis and nausea. Delivering the inhibitor by the inhaled route may improve therapeutic index, and herein we describe GSK256066 (6-({3[(dimethylamino) carb...
متن کاملAnti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
From a series of benzamide derivatives, roflumilast (3-cyclo-propylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) was identified as a potent and selective PDE4 inhibitor. It inhibits PDE4 activity from human neutrophils with an IC(50) of 0.8 nM without affecting PDE1 (bovine brain), PDE2 (rat heart), and PDE3 and PDE5 (human platelets) even at 10,000-fold higher concentrations...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- American journal of physiology. Lung cellular and molecular physiology
دوره 296 6 شماره
صفحات -
تاریخ انتشار 2009